title: Optimizing Suprathel®-therapy by the use of Octenidine-Gel®.
abstract: OBJECTIVE
  A prospective, randomized, non-blinded, clinical study was conducted to evaluate the feasibility and practicability as well as pain reduction and ease of handling of Flammazine® versus Octenidine-Gel® s a primary local antiseptic before synthetic skin substitute application in partial-thickness burns.
  
  
  METHODS
  Thirty patients with a median age of 42 years suffering from second-degree burns were included in the study. Burns were randomly selected, one area was treated with Flammazine®/gauze, another area in the same patient was treated with Octenidine-Gel®/gauze as initial antiseptic treatment. Within 24 h the first gauze change was performed followed by wound inspection, disinfection and synthetic skin substitute application. The study focused on patient pain score, analysis of wound bed and ease of handling of the two local antiseptic agents.
  
  
  RESULTS
  There was a significant difference between Flammazine® versus Octenidine-Gel® regarding patient pain score and ease of handling. Octenidine-Gel® was less painful (p < 0.05) and easier to handle (p < 0.05). There was no significant difference for wound bed evaluation between the two antiseptic agents. A tendency for better wound bed preparation was seen with the use of Octenidine-Gel®.
  
  
  CONCLUSIONS
  Based on the findings of this study Octenidine-Gel® is recommended as a local antiseptic agent, because when compared to Flammazine®, Octenidine-Gel® proved to be better in terms of ease of care, simplicity application, with gentler and faster detachment of the gel from wound surfaces and consequently far less pain during dressing changes.
authors.affiliation: Department of Hand, Plastic and Reconstructive Surgery, Burn Center, BG Trauma Center Ludwigshafen, Plastic and Hand Surgery, University of Heidelberg, Ludwigshafen, Germany.
authors.forename: C A
authors.initials: CA
authors.lastname: Radu
authors.forename: E
authors.initials: E
authors.lastname: Gazyakan
authors.forename: G
authors.initials: G
authors.lastname: Germann
authors.forename: K
authors.initials: K
authors.lastname: Riedel
authors.forename: M
authors.initials: M
authors.lastname: Reichenberger
authors.forename: H
authors.initials: H
authors.lastname: Ryssel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D001458:Bandages; D002056:Burns / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D005782:Gels / Q000627:therapeutic use; D006801:Humans; D007097:Imines; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D011091:Polyesters / Q000627:therapeutic use*; D011446:Prospective Studies; D011725:Pyridines / Q000627:therapeutic use*; D012837:Silver Sulfadiazine / Q000627:therapeutic use; D016038:Skin Transplantation / Q000379:methods; D017768:Skin, Artificial
chemical_list: D000891:Anti-Infective Agents, Local; D005782:Gels; D007097:Imines; D011091:Polyesters; D011725:Pyridines; C527789:poly(lactide-co-trimethylenecarbonate-co-epsilon-caprolactone); C034213:octenidine; D012837:Silver Sulfadiazine